

MAILED  
JUN 07 2002  
DATE CANCELLED  
P & T

U.S. PATENT & TRADEMARK OFFICE  
JUN 06 2002

COPY OF PAPERS  
ORIGINALLY FILED

PATENT

Docket No.: LAY-006CIA

#124  
JUN 13 2002  
6/18/02

Group Art Unit: 1632

Examiner: Anne Marie Baker

Serial No. 09/494,088

Filed: 01/28/2000

In re Application of: McGrogan

For: Production and Use of Dopaminergic Cells to Treat Dopaminergic Deficiencies

TECH CENTER 1600/2900

JUN 13 2002

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Director of Patents, Box \_\_\_\_\_ Washington, D.C. 20231 on 5-28-02, Signed Carolyn Thompson

**RESPONSE TO OFFICE ACTION**  
**AMENDMENT**

Director of Patents  
Washington, D.C. 20231

Dear Examiner:

Applicants respectfully respond to the Office Action dated January 3, 2002, and the interview summary mailed April 29, 2002. The amendments here presented are made for the purposes of better defining the invention, rather than to overcome the rejections for patentability. No presumption should therefore attach that the claims have been narrowed over those earlier presented, or that subject matter or equivalents thereof to which the Applicants are entitled has been surrendered. No new matter has been introduced by these amendments. Reconsideration and allowance is respectfully requested in view of the amendments and the following remarks.

In the Claims:

Sub  
C1  
3

1. (amended) A method of producing dopaminergic neuronal cells, said neuronal cells being derived from neuronal progenitor cells,
  - a. providing neuronal progenitor cells which lack at least one indicator of neuronal cell differentiation;
  - b. treating the neuronal progenitor cells with an inducing agent for a time period sufficient to optimize expression of tyrosine hydroxylase and to induce the